[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

IL148222A0 - Compounds for the treatment of ischemia - Google Patents

Compounds for the treatment of ischemia

Info

Publication number
IL148222A0
IL148222A0 IL14822200A IL14822200A IL148222A0 IL 148222 A0 IL148222 A0 IL 148222A0 IL 14822200 A IL14822200 A IL 14822200A IL 14822200 A IL14822200 A IL 14822200A IL 148222 A0 IL148222 A0 IL 148222A0
Authority
IL
Israel
Prior art keywords
ischemia
compounds
treatment
Prior art date
Application number
IL14822200A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL148222A0 publication Critical patent/IL148222A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • C07D473/34Nitrogen atom attached in position 6, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28Oxygen atom
    • C07D473/30Oxygen atom attached in position 6, e.g. hypoxanthine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
IL14822200A 1999-09-30 2000-09-29 Compounds for the treatment of ischemia IL148222A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15682899P 1999-09-30 1999-09-30
PCT/IB2000/001353 WO2001023399A1 (en) 1999-09-30 2000-09-22 Compounds for the treatment of ischemia

Publications (1)

Publication Number Publication Date
IL148222A0 true IL148222A0 (en) 2002-09-12

Family

ID=22561263

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14822200A IL148222A0 (en) 1999-09-30 2000-09-29 Compounds for the treatment of ischemia

Country Status (41)

Country Link
EP (1) EP1216257B1 (de)
JP (1) JP2003510331A (de)
KR (1) KR100481605B1 (de)
CN (1) CN1374967A (de)
AP (1) AP2002002458A0 (de)
AR (1) AR029887A1 (de)
AT (1) ATE312117T1 (de)
AU (1) AU778185B2 (de)
BG (1) BG106636A (de)
BR (1) BR0014384A (de)
CA (1) CA2386079A1 (de)
CO (1) CO5180581A1 (de)
CR (1) CR6592A (de)
CZ (1) CZ20021020A3 (de)
DE (1) DE60024649D1 (de)
EA (1) EA005422B1 (de)
EC (1) ECSP003682A (de)
EE (1) EE200200172A (de)
GE (1) GEP20043241B (de)
GT (1) GT200000161A (de)
HK (1) HK1049011A1 (de)
HR (1) HRP20020253A2 (de)
HU (1) HUP0202807A3 (de)
IL (1) IL148222A0 (de)
IS (1) IS6286A (de)
MA (1) MA26822A1 (de)
MX (1) MXPA02003308A (de)
MY (1) MY133996A (de)
NO (1) NO20021474L (de)
NZ (1) NZ517177A (de)
OA (1) OA12021A (de)
PA (1) PA8503301A1 (de)
PE (1) PE20010696A1 (de)
PL (1) PL357371A1 (de)
SK (1) SK4182002A3 (de)
TN (1) TNSN00191A1 (de)
TR (1) TR200200843T2 (de)
UA (1) UA73525C2 (de)
WO (1) WO2001023399A1 (de)
YU (1) YU23102A (de)
ZA (1) ZA200202461B (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6803457B1 (en) 1999-09-30 2004-10-12 Pfizer, Inc. Compounds for the treatment of ischemia
EP1241176A1 (de) * 2001-03-16 2002-09-18 Pfizer Products Inc. Purinderivate zur Behandlung von Ischämie
KR20050042225A (ko) * 2001-11-02 2005-05-06 아벤티스 파마슈티칼스 인크. 아데노신 a1/a2 효능제 및 나트륨 수소 교환 억제제를포함하는 약제학적 조성물
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
DE60325572D1 (de) * 2002-04-18 2009-02-12 Cv Therapeutics Inc Methode zur behandlung von herzrhythmusstörungen mit einem a1 adenosin agonist zusammen mit einem beta blocker
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
CN1902171A (zh) * 2003-11-10 2007-01-24 舍林股份公司 用作ccr-5拮抗剂的苄醚胺化合物
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
WO2005092068A2 (en) 2004-03-24 2005-10-06 Fasgen, Llc Novel method of neuroprotection by pharmacological inhibition of amp-activated protein kinase
ES2525319T3 (es) 2004-05-07 2014-12-22 Janssen Pharmaceutica Nv Derivados de pirrolidin-2-ona y piperidin-2-ona como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
WO2006011130A1 (en) * 2004-07-28 2006-02-02 Can-Fite Biopharma Ltd. Adenosine a3 receptor agonists for the treatment of dry eye disorders including sjogren’s syndrome
EP1781331A1 (de) * 2004-08-09 2007-05-09 Université Catholique de Louvain Verwendung von agonisten und antagonisten von beta-adrenozeptoren zur behandlung von arterienerkrankungen
JP5137574B2 (ja) 2004-08-30 2013-02-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 11−ベータヒドロキシステロイドヒドロゲナーゼ阻害剤としての三環式ラクタム誘導体
DE602005017159D1 (de) 2004-08-30 2009-11-26 Janssen Pharmaceutica Nv Oxysteroid-dehydrogenase-inhibitoren
MX2007002449A (es) * 2004-08-30 2007-10-10 Janssen Pharmaceutica Nv Derivados de n-2 adamantanil-2-fenoxi-acetamida como inhibidores de deshidrogenasa 11-beta hidroxiesteroide.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
KR101461263B1 (ko) 2005-10-21 2014-11-17 노파르티스 아게 Il-13에 대항한 인간 항체 및 치료적 용도
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
US20090286779A1 (en) 2006-09-29 2009-11-19 Novartis Ag Pyrazolopyrimidines as lipid kinase inhibitors
WO2008052734A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
JP5584138B2 (ja) 2008-01-11 2014-09-03 ノバルティス アーゲー キナーゼ阻害剤としてのピリミジン類
WO2010088335A1 (en) 2009-01-29 2010-08-05 Novartis Ag Substituted benzimidazoles for the treatment of astrocytomas
US9199102B2 (en) 2009-07-21 2015-12-01 Oradin Pharmaceutical Ltd. A3 adenosine receptor ligands for modulation of pigmentation
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
AU2010283806A1 (en) 2009-08-12 2012-03-01 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
AU2010284254B2 (en) 2009-08-17 2015-09-17 Intellikine, Llc Heterocyclic compounds and uses thereof
WO2011020861A1 (en) 2009-08-20 2011-02-24 Novartis Ag Heterocyclic oxime compounds
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
JP2014505088A (ja) 2011-02-10 2014-02-27 ノバルティス アーゲー C−METチロシンキナーゼ阻害剤としての[1,2,4]トリアゾロ[4,3−b]ピリダジン化合物
US9127000B2 (en) 2011-02-23 2015-09-08 Intellikine, LLC. Heterocyclic compounds and uses thereof
MA34969B1 (fr) 2011-02-25 2014-03-01 Irm Llc Composes et compositions en tant qu inibiteurs de trk
CA2848809A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines as c-met tyrosine kinase
US9174994B2 (en) 2011-11-23 2015-11-03 Intellikine, Llc Enhanced treatment regimens using mTor inhibitors
WO2013149581A1 (en) 2012-04-03 2013-10-10 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
WO2013169939A2 (en) 2012-05-08 2013-11-14 Aeromics, Llc New methods
RU2559776C2 (ru) * 2012-08-20 2015-08-10 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Фармацевтические композиции для лечения цереброваскулярных расстройств и способы их изготовления
CA2906542A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
CN106163506A (zh) * 2013-11-06 2016-11-23 埃罗米克斯公司 新配方
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
RU2611339C2 (ru) * 2014-02-17 2017-02-21 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Фармацевтические композиции с пролонгированным высвобождением для лечения цереброваскулярных расстройств
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
CN107207510B (zh) 2014-07-31 2019-11-29 诺华股份有限公司 联合疗法
RU2582961C1 (ru) * 2015-03-04 2016-04-27 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Фармацевтические композиции в жидких лекарственных формах для лечения цереброваскулярных расстройств и способы их изготовления
RU2712150C1 (ru) * 2019-08-22 2020-01-24 Общество с ограниченной ответственностью "ЦЕНТР ТРАНСФЕРА БИОТЕХНОЛОГИЙ ОКА-Биотех" ПРИМЕНЕНИЕ ТЕТРААЦЕТИЛИРОВАННОГО 5-АМИНО-4-КАРБАМОИЛИМИДАЗОЛИЛ-1-β-D-РИБОФУРАНОЗИДА В КАЧЕСТВЕ ИНГИБИТОРА ПРОТЕИНКИНАЗЫ Cδ
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK62692D0 (de) * 1992-05-14 1992-05-14 Novo Nordisk As
TW336938B (en) * 1992-05-21 1998-07-21 Pfizer Calcium channel blocking polypeptides from filistata hibernalis
US5773423A (en) * 1993-07-13 1998-06-30 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists

Also Published As

Publication number Publication date
AU778185B2 (en) 2004-11-18
WO2001023399A1 (en) 2001-04-05
CA2386079A1 (en) 2001-04-05
SK4182002A3 (en) 2003-04-01
MA26822A1 (fr) 2004-12-20
KR100481605B1 (ko) 2005-04-08
OA12021A (en) 2006-04-19
KR20020034206A (ko) 2002-05-08
EP1216257B1 (de) 2005-12-07
JP2003510331A (ja) 2003-03-18
YU23102A (sh) 2006-01-16
TR200200843T2 (tr) 2002-07-22
GT200000161A (es) 2002-03-22
EA005422B1 (ru) 2005-02-24
IS6286A (is) 2002-02-26
ECSP003682A (es) 2002-04-23
CO5180581A1 (es) 2002-07-30
ZA200202461B (en) 2003-05-28
DE60024649D1 (de) 2006-01-12
AR029887A1 (es) 2003-07-23
HUP0202807A2 (hu) 2002-12-28
EE200200172A (et) 2003-06-16
TNSN00191A1 (fr) 2005-11-10
EA200200316A1 (ru) 2002-08-29
CR6592A (es) 2004-02-23
PL357371A1 (en) 2004-07-26
CZ20021020A3 (cs) 2003-04-16
GEP20043241B (en) 2004-05-25
HUP0202807A3 (en) 2005-02-28
HK1049011A1 (zh) 2003-04-25
ATE312117T1 (de) 2005-12-15
CN1374967A (zh) 2002-10-16
NO20021474D0 (no) 2002-03-25
AP2002002458A0 (en) 2002-06-30
EP1216257A1 (de) 2002-06-26
UA73525C2 (en) 2005-08-15
PA8503301A1 (es) 2003-06-30
NO20021474L (no) 2002-05-22
NZ517177A (en) 2003-10-31
BR0014384A (pt) 2002-07-02
MXPA02003308A (es) 2002-10-04
MY133996A (en) 2007-11-30
BG106636A (bg) 2003-01-31
PE20010696A1 (es) 2001-07-05
HRP20020253A2 (en) 2004-04-30
AU7035200A (en) 2001-04-30

Similar Documents

Publication Publication Date Title
HUP0202807A3 (en) Compounds for the treatment of ischemia
ZA991578B (en) Compounds for the treatment of ischemia.
IL174917A0 (en) Compounds useful as anti-inflammatory agents
GB2357761B (en) Compounds
GB9904933D0 (en) Compounds
AU8322401A (en) Indole compounds useful for the treatment of cancer
IL133760A0 (en) Composition for the treatment of dandruff
GB9900222D0 (en) Therapeutic compounds
GB9902399D0 (en) Compounds
GB9904930D0 (en) Thiazoloindolinone compounds
HK1043938A1 (en) Composition for the treatment of psoriasis
GB9905771D0 (en) Compounds
GB9921718D0 (en) Therapeutic compounds
GB9929432D0 (en) Therapeutic compounds
GB9916886D0 (en) Therapeutic compounds
GB9914952D0 (en) Therapeutic compounds
GB9907227D0 (en) Therapeutic compounds
GB9903090D0 (en) Therapeutic compounds
GB9903296D0 (en) Compounds
GB9903420D0 (en) Compounds
GB9903268D0 (en) Compounds
GB9903288D0 (en) Compounds
GB9903290D0 (en) Compounds
GB9903291D0 (en) Compounds
GB9903273D0 (en) Compounds